Key result
Treatment of complex coronary lesions with a device-only strategy using the novel Selution SLR sirolimus-coated balloon was safe and associated with a 6.8% rate of major adverse cardiovascular events at 1-year follow-up.
Why the study?
In-stent restenosis and very late stent thrombosis remain concerns despite latest generation drug-eluting stents, motivating evaluation of a novel sirolimus-coated balloon in complex coronary lesions.
Observational (n=78)
No
BACKGROUND: Limus-eluting stents have become the mainstay for percutaneous coronary intervention (PCI). However, even with the latest generation drug-eluting stent, in-stent restenosis and very late stent thrombosis remain a concern. The Selution SLR™ drug-coated balloon (DCB) is a novel sirolimus-coated balloon that provides a controlled release of the antiproliferative drug. Herein we evaluated its performance in a real-world patient cohort with complex coronary artery lesions. METHODS: Patients undergoing PCI using the Selution SLR™ DCB were analyzed from the prospective SIROOP registry. We evaluated procedural success and clinical outcomes, including major adverse cardiovascular event (MACE), cardiac death, target vessel myocardial infarction and target lesion revascularization. RESULTS: From September 2020 to April 2021, we enrolled 78 patients (87 lesions) treated using a "DCB only" strategy. The mean age was 66.7 ± 10.4 years and 28 (36%) presented with an acute coronary syndrome. Almost all lesions were type B2/C 86 (99%) and 49 (63%) had moderate to severe calcifications. Procedural success was 100%. After a median follow-up of 11.2 months (interquartile range: 10.0-12.6), MACE occurred in 5 (6.8%) patients. No acute vessel closure was observed. CONCLUSIONS: In complex coronary lesions, a "DCB only" strategy using the Selution SLR™ DCB is not just safe and feasible, but also seems to be associated with a low rate of MACE at 1-year follow-up. Our promising results warrant further evaluation in a dedicated comparative trial.
No takes yet. Share an insight, caveat, or question.
Madanchi et al. (2022) conducted an observational in Coronary artery disease (n=78). Selution SLR sirolimus-coated balloon was evaluated on Major adverse cardiovascular event (MACE) defined as a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization. Treatment of complex coronary lesions with a device-only strategy using the novel Selution SLR sirolimus-coated balloon was safe and associated with a 6.8% rate of major adverse cardiovascular events at 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: